Ryan D. Stephenson

878 citations

18 papers · 539 indexed · 1 hit paper · h-index 9

Impact in

Pulmonary and Respiratory Medicine top 10%
- Prostate Cancer Treatment and Research
- Ferroptosis and cancer prognosis
- Prostate Cancer Diagnosis and Treatment
Oncology top 10%
- Bone health and treatments
- Cancer Immunotherapy and Biomarkers

Papers in

Oncology 9
- Bone health and treatments 2
- Cancer Treatment and Pharmacology 2
Pulmonary and Respiratory Medicine 10
- Prostate Cancer Treatment and Research 9
- Prostate Cancer Diagnosis and Treatment 2

Co-authors: Howard I. Scher Michael J. Morris Steven M. Larson Glenn Heller Xiaoyu Jia Elizabeth R. Dennis Susan F. Slovin Heiko Schöder
Journals: Journal of Clinical Oncology (6 papers)Cancer (1 paper)The Prostate (1 paper)ESMO Open (1 paper)European Urology (1 paper)
Partner nations: United States Malaysia United Kingdom

In The Last Decade

Ryan D. Stephenson

16 papers receiving 524 citations

Hit Papers

align trajectories log scale

Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers 2021 · 196 citations

Peers

Countries citing papers authored by Ryan D. Stephenson

Since Specialization

Citations

This map shows the geographic impact of Ryan D. Stephenson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryan D. Stephenson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryan D. Stephenson more than expected).

Fields of papers citing papers by Ryan D. Stephenson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryan D. Stephenson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryan D. Stephenson. The network helps show where Ryan D. Stephenson may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Ryan D. Stephenson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ryan D. Stephenson Line = papers co-authored together Ryan D. Stephenson links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work
1	PIK3/Akt/mTOR pathway alterations in metastatic castration‐sensitive prostate cancer The Prostate ·Philip Sutera, Jongmyung Kim, Ritesh Kumar, Rebecca A. Deek, Ryan D. Stephenson, Tina Mayer, Biren Saraiya, Saum Ghodoussipour, Thomas L. Jang, David Golombos, Vignesh T. Packiam, Ronald D. Ennis, Lara Hathout, Leon Christ, Ozan Cem Güler, Cem Önal, Phuoc T. Tran, Matthew P. Deek	2024	2
2	Results from phase 1a/1b analyses of TTX-080, a first in class HLA-G antagonist, in combination with cetuximab in patients (pts) with metastatic colorectal cancer and head and neck squamous cell carcinoma. Journal of Clinical Oncology ·Susanna V. Ulahannan, Thomas U. Marron, Haeseong Park, John M. Kaczmar, Ryan D. Stephenson, Nehal J. Lakhani, Greg Andrew Durm, Jaspreet Singh Grewal, Anthony B. El-Khoueiry, Jason J. Luke, Courtney Beers, Swaminathan Murugappan, Patricia LoRusso, Douglas R. Adkins, J. Randolph Hecht	2024	2
3	Enriched class II HLA inherence in patients with checkpoint inhibitor‐associated bullous pemphigoid International Journal of Dermatology ·Andrea Young, Adam C. Berger, Ryan D. Stephenson, Darius Mehregan, Bahar Dasgeb	2024	0
4	HLA inherence as a potential parameter in checkpoint inhibitor-associated autoimmune adverse event assessment Frontiers in Medicine ·Andrea Young, Cem Çağlar Dallı, Deborah Toppmeyer, Ryan D. Stephenson, Lisa Denzin, Bahar Dasgeb	2024	4
5	BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm). Journal of Clinical Oncology ·Maha Hussain, Masha Kocherginsky, Neeraj Agarwal, Nabil Adra, Jingsong Zhang, Channing J. Paller, Joel Picus, Zachery R. Reichert, Russell Z. Szmulewitz, Scott T. Tagawa, Timothy M. Kuzel, Latifa A. Bazzi, Stephanie Daignault‐Newton, Young E. Whang, Robert Dreicer, Ryan D. Stephenson, Matthew B. Rettig, Daniel H. Shevrin, Arul M. Chinnaiyan, Emmanuel S. Antonarakis	2024	13
6	Metastasis-Directed Therapy for Oligometastatic Castration-Sensitive Prostate Cancer: An Alternative to ADT? Current Urology Reports ·Nikhil Samudrala, John Pfail, 井ノ上景子, Biren Saraiya, Tina Mayer, Ryan D. Stephenson, Ronald D. Ennis, Lara Hathout, Matthew P. Deek, Saum Ghodoussipour, Thomas L. Jang	2023	1
7	Use of immune checkpoint inhibitors in solid organ transplant recipients with advanced cutaneous malignancies SHILAP Revista de lepidopterología ·Бекоев Руслан Павлович, Hao Liu, 直己門田, Ryan D. Stephenson, Roman Groisberg, Sarah A. Weiss	2023	3
8	Top Ten Tips Palliative Care Clinicians Should Know About Urological Care Journal of Palliative Medicine ·Martin Umbehr, Adrian Wagg, António Jorge Ferreira Vaz, Jodi Antonelli, Bilal Chughtai, Thomas L. Jang, Danyang Xu, Biren Saraiya, Ryan D. Stephenson, Christina Sze, Andreas Wiedemann, Christopher A. Jones, Mathias Schlögl	2022	3
9	Virtual Tumor Board Increases Provider Attendance and Case Presentations JCO Oncology Practice ·Catherine H. Davis, Jason Ho, Ryan D. Stephenson, David A. August, Chloe S. Dickinson, Joseph Weiner, H. Richard Alexander, Henry A. Pitt, Adam C. Berger	2022	13
10	S2209 A Rare Case of BRAF/MEK Inhibitor-Induced Colitis The American Journal of Gastroenterology ·O. Braadbaart, 彩起子山田, Ryan D. Stephenson, Lea Ann Chen	2022	0
11	Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers ESMO Open ·Matteo Palmeri, Janice M. Mehnert, Ann W. Silk, Salma K. Jabbour, Shridar Ganesan, 公藤田, Gregory Riedlinger, Ryan D. Stephenson, Alexandre Buckley de Meritens, Aliza Leiser, Tina Mayer, Nancy Chan, Kristen Spencer, Eugenia Girda, Jyoti Malhotra, Timothy A. Chan, Vivek Subbiah, Roman Groisberg Hit paper breakdown →	2021	196
12	Repetitively dosed docetaxel and ¹⁵³samarium‐EDTMP as an antitumor strategy for metastatic castration‐resistant prostate cancer Cancer ·Karen A. Autio, Neeta Pandit‐Taskar, Jorge A. Carrasquillo, Ryan D. Stephenson, Susan F. Slovin, Dana E. Rathkopf, Christina Hong, Glenn Heller, Howard I. Scher, Steven M. Larson, Michael J. Morris	2013	16
13	Bone Scan Index: A Quantitative Treatment Response Biomarker for Castration-Resistant Metastatic Prostate Cancer Journal of Clinical Oncology ·Elizabeth R. Dennis, Xiaoyu Jia, Д Марцинковская Татьяна, Ryan D. Stephenson, Heiko Schöder, Josef J. Fox, Glenn Heller, Howard I. Scher, Steven M. Larson, Michael J. Morris	2012	134
14	Phase 1 Trial of High-Dose Exogenous Testosterone in Patients with Castration-Resistant Metastatic Prostate Cancer European Urology ·Michael J. Morris, Ltd. Cambridge Instrument Co., William Kevin Kelly, Susan F. Slovin, Ryan D. Stephenson, Ronald Santiago Cortes-Santamaria, A. Delacruz, Tracy Curley, Lawrence H. Schwartz, Howard I. Scher	2009	64
15	Phase I/II study of docetaxel and ¹⁵³Sm for castrate metastatic prostate cancer (CMPC): Summary of dose-escalation cohorts and first report on the expansion cohort Journal of Clinical Oncology ·Michael J. Morris, Neeta Pandit‐Taskar, Ryan D. Stephenson, Christina Hong, Susan F. Slovin, Dana E. Rathkopf, David B. Solit, Jorge A. Carrasquillo, Steven M. Larson, Howard I. Scher	2009	6
16	Phase I Study of Samarium-153 Lexidronam With Docetaxel in Castration-Resistant Metastatic Prostate Cancer Journal of Clinical Oncology ·Michael J. Morris, Neeta Pandit‐Taskar, Jorge A. Carrasquillo, Chaitanya Divgi, Susan F. Slovin, William Kevin Kelly, Dana E. Rathkopf, Gretchen A. Gignac, David B. Solit, Lawrence H. Schwartz, Ryan D. Stephenson, Christina Hong, A. Delacruz, Tracy Curley, Glenn Heller, Xiaoyu Jia, Joseph A. O’Donoghue, Steven M. Larson, Howard I. Scher	2009	64
17	Phase I study of docetaxel (Tax) and ¹⁵³Sm repetitively administered for castrate metastatic prostate cancer (CMPC) Journal of Clinical Oncology ·Michael J. Morris, Neeta Pandit‐Taskar, Ryan D. Stephenson, Christina Hong, Susan F. Slovin, D. Solit, Dana E. Rathkopf, Jorge A. Carrasquillo, Steven M. Larson, Howard I. Scher	2008	8
18	Diving Accidents in Sports Divers in Orkney Waters Scottish Medical Journal ·A.J. Trevett, В.Д. Микоян, V. C. Monteiro, Madison Tyle, John Ross, Stephen Watt, Ryan D. Stephenson	2001	10

About Ryan D. Stephenson

Ryan D. Stephenson is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, Genetics and Immunology and Allergy, having authored 18 papers that have together received 539 indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (9 papers), Radiopharmaceutical Chemistry and Applications (6 papers), Bone health and treatments (2 papers), Autoimmune Bullous Skin Diseases (2 papers), Cancer Treatment and Pharmacology (2 papers), Hormonal and reproductive studies (2 papers), Prostate Cancer Diagnosis and Treatment (2 papers) and DNA Repair Mechanisms (1 paper). The work is most often cited by research in Pulmonary and Respiratory Medicine (370 citations), Oncology (281 citations), Radiology, Nuclear Medicine and Imaging (185 citations), Cancer Research (98 citations) and Endocrinology, Diabetes and Metabolism (40 citations). Ryan D. Stephenson has collaborated with scholars based in United States, Malaysia and United Kingdom. Frequent co-authors include Howard I. Scher, Michael J. Morris, Steven M. Larson, Glenn Heller, Xiaoyu Jia, Elizabeth R. Dennis, Susan F. Slovin, Heiko Schöder, Josef J. Fox and Matteo Palmeri. Their work appears in journals such as Journal of Clinical Oncology, Cancer, The Prostate, ESMO Open and European Urology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact